Characteristics of Patients Who Achieve Long-Term Response with PD-1 Blockade

Conference Correspondent

To learn more about the frequency, characteristics, and predictors of long-term response to PD-1 inhibitors, patients from 2 institutions (Memorial Sloan Kettering Cancer Center [MSKCC] and Dana-Farber Cancer Institute [DFCI]) who were diagnosed with advanced non–small-cell lung cancer (NSCLC) and treated with anti–PD-1 or PD-L1 therapy were examined. Responses were assessed by RECIST. Long-term responders had responses (partial response [PR] or complete response [CR]) lasting ≥24 months. Short-term responders had PR or CR lasting <12 months. Comparisons were also made with patients who had progressive disease. PD-L1 expression was assessed by immunohistochemistry. Tumor mutation burden (TMB) was assessed by targeted next-generation sequencing. High TMB was defined as greater than or equal to the median of the cohort.  

Of 2382 patients, 6.3% (95% confidence interval [CI], 5.3%-7.4%) were long-term responders, with similar rates in both the MSKCC and DFCI cohorts. Short-term responses occurred in 6% of all patients. Overall survival was longer in long-term responders compared with short-term responders (median not reached vs 19.6 months; hazard ratio [HR], 0.07; P <.001 in the MSKCC cohort; median not reached vs 18.0 months; HR, 0.08; P <.001 in the DFCI cohort). Long-term responders had deeper responses compared with short-term responders (median best overall response, –73% vs –39%; P <.001).

Patients with long-term responses were also significantly more likely to be younger (<65 years old) with higher TMB (≥ median mutations per megabase) compared with both short-term responders and progressors. The rate of long-term response was enriched among patients with both high TMB and high PD-L1 compared with those with low TMB and low PD-L1 (16% vs 2%; P <.001).

Two percent of patients with sensitizing EGFR mutations (N = 243) achieved long-term response to PD-1 inhibition. Loss of function variants in ARID1A (14% vs 2%), PTEN (8% vs 0%), and KEAP1 (12% vs 2%) were enriched in long-term responders compared with short-term responders (P <.05 for each). Among patients with KRAS mutations, the rate of long-term response was higher in those with co-mutation with TP53 compared with STK11 (12% vs 2%; P = .01).

Researchers concluded that long-term response, defined as ongoing response for ≥24 months, to PD-1 blockade is an uncommon but profound clinical outcome in metastatic lung cancer. Younger age and high TMB correlate with long-term responders. The combination of high TMB and high PD-L1 enriches for long-term responders but not short-term responders. Features that predict long-term response may be distinct from those predicting initial response.

Reference

  • Luo J, Bandlamudi C, Ricciuti B, et al. Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer. J Clin Oncol. 2020;38:suppl (abstract 9549).
Related Articles
ASCO 2020 Lung Cancer Highlights
Conference Correspondent

Although the American Society of Clinical Oncology (ASCO) 2020 meeting was held virtually because of the COVID-19 pandemic, hundreds of abstracts, posters, and presentations were still made available to inform clinicians on the latest developments in the treatment of lung cancer. This publication features some of the key highlights from the meeting, which can be used to improve the management and care of patients with the disease.

Impact of Immune-Related Adverse Events on Checkpoint Inhibitor Consolidation Therapy in Stage III NSCLC
Conference Correspondent
Immune-related adverse events did not affect the clinical benefit of consolidation checkpoint inhibitor therapy after chemoradiation in stage III non–small-cell lung cancer.
Patterns of Acquired Resistance in Patients with NSCLC Who Receive PD-1 Inhibitors
Conference Correspondent
The frequency and durability of outcomes associated with acquired resistance to PD-1 inhibition in non–small-cell lung cancer are presented.
Last modified: November 5, 2020

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code